Publication

Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes

Schievink, B., Kropelin, T., Mulder, S., Parving, H. -H., Remuzzi, G., Dwyer, J., Vemer, P., de Zeeuw, D. & Heerspink, H. J. L., Jan-2016, In : Diabetes obesity & metabolism. 18, 1, p. 64-71 8 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Schievink, B., Kropelin, T., Mulder, S., Parving, H. -H., Remuzzi, G., Dwyer, J., ... Heerspink, H. J. L. (2016). Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes. Diabetes obesity & metabolism, 18(1), 64-71. https://doi.org/10.1111/dom.12583

Author

Schievink, B. ; Kropelin, T. ; Mulder, S. ; Parving, H. -H. ; Remuzzi, G. ; Dwyer, J. ; Vemer, P. ; de Zeeuw, D. ; Heerspink, H. J. Lambers. / Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes. In: Diabetes obesity & metabolism. 2016 ; Vol. 18, No. 1. pp. 64-71.

Harvard

Schievink, B, Kropelin, T, Mulder, S, Parving, H-H, Remuzzi, G, Dwyer, J, Vemer, P, de Zeeuw, D & Heerspink, HJL 2016, 'Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes', Diabetes obesity & metabolism, vol. 18, no. 1, pp. 64-71. https://doi.org/10.1111/dom.12583

Standard

Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes. / Schievink, B.; Kropelin, T.; Mulder, S.; Parving, H. -H.; Remuzzi, G.; Dwyer, J.; Vemer, P.; de Zeeuw, D.; Heerspink, H. J. Lambers.

In: Diabetes obesity & metabolism, Vol. 18, No. 1, 01.2016, p. 64-71.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Schievink B, Kropelin T, Mulder S, Parving H-H, Remuzzi G, Dwyer J et al. Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes. Diabetes obesity & metabolism. 2016 Jan;18(1):64-71. https://doi.org/10.1111/dom.12583


BibTeX

@article{ea513abc76a44b1a8feb04aece749ada,
title = "Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes",
abstract = "Aims: To develop and validate a model to simulate progression of diabetic kidney disease (DKD) from early onset until end-stage renal disease (ESRD), and to assess the effect of renin-angiotensin system (RAS) intervention in early, intermediate and advanced stages of DKD.Methods: We used data from the BENEDICT, IRMA-2, RENAAL and IDNT trials that assessed effects of RAS intervention in patients with type 2 diabetes. We built a model with discrete disease stages based on albuminuria and estimated glomerular filtration rate (eGFR). Using survival analyses, we assessed the effect of RAS intervention on delaying ESRD in early [eGFR>60 ml/min/1.73m(2) and albumin: creatinine ratio (ACR) 300 mg/g) stages of DKD for patients in different age groups.Results: For patients at early, intermediate and advanced stage of disease, whose mean age was 60 years and who received placebo, the median time to ESRD was 21.4, 10.8 and 4.7 years, respectively. RAS intervention delayed the predicted time to ESRD by 4.2, 3.6 and 1.4 years, respectively. The benefit of early RAS intervention was more pronounced in younger patients; for example, for patients with a mean age of 45 years, RAS intervention at early, intermediate or advanced stage delayed ESRD by 5.9, 4.0 and 1.1 years versus placebo.Conclusions: RAS intervention early in the course of proteinuric DKD is more beneficial than late intervention in delaying ESRD.",
keywords = "albuminuria, kidney disease, RAS inhibitors, type 2 diabetes, CHRONIC KIDNEY-DISEASE, CARDIOVASCULAR OUTCOMES, OVERT NEPHROPATHY, UNITED-STATES, MICROALBUMINURIA, PREVENTION, IRBESARTAN, MELLITUS, ADOLESCENTS, PREVALENCE",
author = "B. Schievink and T. Kropelin and S. Mulder and Parving, {H. -H.} and G. Remuzzi and J. Dwyer and P. Vemer and {de Zeeuw}, D. and Heerspink, {H. J. Lambers}",
note = "This article is protected by copyright. All rights reserved.",
year = "2016",
month = "1",
doi = "10.1111/dom.12583",
language = "English",
volume = "18",
pages = "64--71",
journal = "Diabetes obesity & metabolism",
issn = "1462-8902",
publisher = "Wiley",
number = "1",

}

RIS

TY - JOUR

T1 - Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes

AU - Schievink, B.

AU - Kropelin, T.

AU - Mulder, S.

AU - Parving, H. -H.

AU - Remuzzi, G.

AU - Dwyer, J.

AU - Vemer, P.

AU - de Zeeuw, D.

AU - Heerspink, H. J. Lambers

N1 - This article is protected by copyright. All rights reserved.

PY - 2016/1

Y1 - 2016/1

N2 - Aims: To develop and validate a model to simulate progression of diabetic kidney disease (DKD) from early onset until end-stage renal disease (ESRD), and to assess the effect of renin-angiotensin system (RAS) intervention in early, intermediate and advanced stages of DKD.Methods: We used data from the BENEDICT, IRMA-2, RENAAL and IDNT trials that assessed effects of RAS intervention in patients with type 2 diabetes. We built a model with discrete disease stages based on albuminuria and estimated glomerular filtration rate (eGFR). Using survival analyses, we assessed the effect of RAS intervention on delaying ESRD in early [eGFR>60 ml/min/1.73m(2) and albumin: creatinine ratio (ACR) 300 mg/g) stages of DKD for patients in different age groups.Results: For patients at early, intermediate and advanced stage of disease, whose mean age was 60 years and who received placebo, the median time to ESRD was 21.4, 10.8 and 4.7 years, respectively. RAS intervention delayed the predicted time to ESRD by 4.2, 3.6 and 1.4 years, respectively. The benefit of early RAS intervention was more pronounced in younger patients; for example, for patients with a mean age of 45 years, RAS intervention at early, intermediate or advanced stage delayed ESRD by 5.9, 4.0 and 1.1 years versus placebo.Conclusions: RAS intervention early in the course of proteinuric DKD is more beneficial than late intervention in delaying ESRD.

AB - Aims: To develop and validate a model to simulate progression of diabetic kidney disease (DKD) from early onset until end-stage renal disease (ESRD), and to assess the effect of renin-angiotensin system (RAS) intervention in early, intermediate and advanced stages of DKD.Methods: We used data from the BENEDICT, IRMA-2, RENAAL and IDNT trials that assessed effects of RAS intervention in patients with type 2 diabetes. We built a model with discrete disease stages based on albuminuria and estimated glomerular filtration rate (eGFR). Using survival analyses, we assessed the effect of RAS intervention on delaying ESRD in early [eGFR>60 ml/min/1.73m(2) and albumin: creatinine ratio (ACR) 300 mg/g) stages of DKD for patients in different age groups.Results: For patients at early, intermediate and advanced stage of disease, whose mean age was 60 years and who received placebo, the median time to ESRD was 21.4, 10.8 and 4.7 years, respectively. RAS intervention delayed the predicted time to ESRD by 4.2, 3.6 and 1.4 years, respectively. The benefit of early RAS intervention was more pronounced in younger patients; for example, for patients with a mean age of 45 years, RAS intervention at early, intermediate or advanced stage delayed ESRD by 5.9, 4.0 and 1.1 years versus placebo.Conclusions: RAS intervention early in the course of proteinuric DKD is more beneficial than late intervention in delaying ESRD.

KW - albuminuria

KW - kidney disease

KW - RAS inhibitors

KW - type 2 diabetes

KW - CHRONIC KIDNEY-DISEASE

KW - CARDIOVASCULAR OUTCOMES

KW - OVERT NEPHROPATHY

KW - UNITED-STATES

KW - MICROALBUMINURIA

KW - PREVENTION

KW - IRBESARTAN

KW - MELLITUS

KW - ADOLESCENTS

KW - PREVALENCE

U2 - 10.1111/dom.12583

DO - 10.1111/dom.12583

M3 - Article

VL - 18

SP - 64

EP - 71

JO - Diabetes obesity & metabolism

JF - Diabetes obesity & metabolism

SN - 1462-8902

IS - 1

ER -

ID: 24128886